544 related articles for article (PubMed ID: 33153902)
1. SARS-CoV-2 convalescent plasma therapy in pediatric patient after hematopoietic stem cell transplantation.
Balashov D; Trakhtman P; Livshits A; Kovalenko I; Tereshenko G; Solopova G; Petraikina E; Maschan A; Novichkova G
Transfus Apher Sci; 2021 Feb; 60(1):102983. PubMed ID: 33153902
[TBL] [Abstract][Full Text] [Related]
2. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
3. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
4. High-throughput detection of antibodies targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples.
Anand SP; Prévost J; Richard J; Perreault J; Tremblay T; Drouin M; Fournier MJ; Lewin A; Bazin R; Finzi A
Transfusion; 2021 May; 61(5):1377-1382. PubMed ID: 33604922
[TBL] [Abstract][Full Text] [Related]
5. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis.
Senefeld JW; Franchini M; Mengoli C; Cruciani M; Zani M; Gorman EK; Focosi D; Casadevall A; Joyner MJ
JAMA Netw Open; 2023 Jan; 6(1):e2250647. PubMed ID: 36633846
[TBL] [Abstract][Full Text] [Related]
7. The use of convalescent plasma for pediatric patients with SARS-CoV-2: A systematic literature review.
Zaffanello M; Piacentini G; Nosetti L; Franchini M
Transfus Apher Sci; 2021 Apr; 60(2):103043. PubMed ID: 33388249
[TBL] [Abstract][Full Text] [Related]
8. Treatment of immunocompromised COVID-19 patients with convalescent plasma.
Fung M; Nambiar A; Pandey S; Aldrich JM; Teraoka J; Freise C; Roberts J; Chandran S; Hays SR; Bainbridge E; DeVoe C; Roque Gardner A; Yokoe D; Henrich TJ; Babik JM; Chin-Hong P
Transpl Infect Dis; 2021 Apr; 23(2):e13477. PubMed ID: 32989856
[TBL] [Abstract][Full Text] [Related]
9. Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk Patients.
Thümmler L; Lindemann M; Horn PA; Lenz V; Konik M; Gäckler A; Boss K; Theodoropoulos F; Besa V; Taube C; Brenner T; Witzke O; Krawczyk A; Rohn H
Viruses; 2022 Dec; 15(1):. PubMed ID: 36680159
[TBL] [Abstract][Full Text] [Related]
10. Convalescent Plasma Therapy in Immunocompromised Patients Infected With the BA.1 or BA.2 Omicron SARS-CoV-2.
Richier Q; De Valence B; Chopin D; Gras E; Levi LI; Abi Aad Y; Pacanowski J; Meynard JL; Plaçais L; Fey D; Couture P; Martin-Blondel G; Pestre V; Woessner J; Ancellin S; Weyrich P; Carpentier B; Idri S; Tiberghien P; Surgers L; Hueso T; Lacombe K
Influenza Other Respir Viruses; 2024 Mar; 18(3):e13272. PubMed ID: 38501337
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 in allogeneic stem cell transplant: high false-negative probability and role of CRISPR and convalescent plasma.
Niu A; McDougal A; Ning B; Safa F; Luk A; Mushatt DM; Nachabe A; Zwezdaryk KJ; Robinson J; Peterson T; Socola F; Safah H; Hu T; Saba NS
Bone Marrow Transplant; 2020 Dec; 55(12):2354-2356. PubMed ID: 32541689
[No Abstract] [Full Text] [Related]
12. First case of convalescent plasma transfusion in a child with COVID-19-associated severe aplastic anemia.
Figlerowicz M; Mania A; Lubarski K; Lewandowska Z; Służewski W; Derwich K; Wachowiak J; Mazur-Melewska K
Transfus Apher Sci; 2020 Oct; 59(5):102866. PubMed ID: 32636116
[TBL] [Abstract][Full Text] [Related]
13. No SARS-CoV-2 RNA detected in the convalescent plasma of COVID-19 patients with different disease severity.
Nomoto H; Kutsuna S; Okuma K; Kuramitsu M; Tezuka K; Ikebe E; Saito S; Kinoshita N; Terada M; Endo M; Suzuki T; Miyazato Y; Nakamoto T; Inada M; Hamaguchi I; Ohmagari N
J Infect Chemother; 2021 Apr; 27(4):653-655. PubMed ID: 33487533
[TBL] [Abstract][Full Text] [Related]
14. Case Report: Convalescent Plasma, a Targeted Therapy for Patients with CVID and Severe COVID-19.
Van Damme KFA; Tavernier S; Van Roy N; De Leeuw E; Declercq J; Bosteels C; Maes B; De Bruyne M; Bogaert D; Bosteels V; Hoste L; Naesens L; Maes P; Grifoni A; Weiskopf D; Sette A; Depuydt P; Van Braeckel E; Haerynck F; Lambrecht BN
Front Immunol; 2020; 11():596761. PubMed ID: 33329586
[TBL] [Abstract][Full Text] [Related]
15. Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters.
Takamatsu Y; Imai M; Maeda K; Nakajima N; Higashi-Kuwata N; Iwatsuki-Horimoto K; Ito M; Kiso M; Maemura T; Takeda Y; Omata K; Suzuki T; Kawaoka Y; Mitsuya H
J Virol; 2022 Feb; 96(4):e0155121. PubMed ID: 34818068
[TBL] [Abstract][Full Text] [Related]
16. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T
Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160
[TBL] [Abstract][Full Text] [Related]
17. Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway.
D'Abramo A; Vita S; Maffongelli G; Beccacece A; Agrati C; Cimini E; Colavita F; Giancola ML; Cavasio A; Nicastri E;
Front Immunol; 2022; 13():911339. PubMed ID: 35711444
[TBL] [Abstract][Full Text] [Related]
18. Persistence of SARS-CoV-2 nasopharyngeal swab PCR positivity in COVID-19 convalescent plasma donors.
Ikegami S; Benirschke R; Flanagan T; Tanna N; Klein T; Elue R; Debosz P; Mallek J; Wright G; Guariglia P; Kang J; Gniadek TJ
Transfusion; 2020 Dec; 60(12):2962-2968. PubMed ID: 32840002
[TBL] [Abstract][Full Text] [Related]
19. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
Trials; 2021 May; 22(1):342. PubMed ID: 34001174
[TBL] [Abstract][Full Text] [Related]
20. Case Report: Convalescent Plasma Achieves SARS-CoV-2 Viral Clearance in a Patient With Persistently High Viral Replication Over 8 Weeks Due to Severe Combined Immunodeficiency (SCID) and Graft Failure.
Keitel V; Bode JG; Feldt T; Walker A; Müller L; Kunstein A; Klindt C; Killer A; Senff T; Timm J; Ostermann P; Damagnez M; Lübke N; Adams O; Schaal H; Antoch G; Neubert J; Albrecht P; Meuth S; Elben S; Mohring A; Fischer JC; Bölke E; Hoenig M; Schulz AS; Luedde T; Jensen B
Front Immunol; 2021; 12():645989. PubMed ID: 34012436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
